Piper Sandler analyst David Westenberg raised the firm’s price target on GeneDx (WGS) to $160 from $140 following quarterly results. The firm keeps an Overweight rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS: